These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 36692913)

  • 21. Reimbursement of Drugs for Rare Diseases through the Public Healthcare System in Canada: Where Are We Now?
    Menon D; Clark D; Stafinski T
    Healthc Policy; 2015 Aug; 11(1):15-32. PubMed ID: 26571466
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Health technology assessment of new drugs for rare disorders in Canada: impact of disease prevalence and cost.
    Rawson NS
    Orphanet J Rare Dis; 2017 Mar; 12(1):59. PubMed ID: 28330479
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of the copayment reduction system on accessibility to orphan drugs in South Korea.
    Hwang SE; Kim M; Hong Y; Lee D; Kim T; Park J; Bae J; Lee JH
    Expert Rev Pharmacoecon Outcomes Res; 2023 Jun; 23(5):519-525. PubMed ID: 36922505
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Guest Editor's Response to "Canadians Need Improved Access to Drugs for Rare Diseases, Not More Denial".
    Lexchin J
    Healthc Pap; 2023 Jul; 21(3):70-71. PubMed ID: 37887173
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Market access for medicines treating rare diseases: Association between specialised processes for orphan medicines and funding recommendations.
    Fontrier AM
    Soc Sci Med; 2022 Aug; 306():115119. PubMed ID: 35700552
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characteristics of drugs for ultra-rare diseases versus drugs for other rare diseases in HTA submissions made to the CADTH CDR.
    Richter T; Janoudi G; Amegatse W; Nester-Parr S
    Orphanet J Rare Dis; 2018 Feb; 13(1):15. PubMed ID: 29386040
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expensive Drugs for Rare Diseases in Canada: Time for Action Everywhere and by Everyone.
    Sirrs S; Anderson H; Jiwani B; Lun E; Nakagawa B; Regier D; Rizzardo S; McFarlane A
    Healthc Pap; 2023 Jan; 21(1):74-80. PubMed ID: 36692920
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Conditional approval of cancer drugs in Canada: accountability and impact on public funding.
    Andersen SK; Penner N; Chambers A; Trudeau ME; Chan KKW; Cheung MC
    Curr Oncol; 2019 Feb; 26(1):e100-e105. PubMed ID: 30853815
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regulatory approval and public drug plan listing of new drugs for rare disorders in Canada and New Zealand.
    Rawson NSB
    J Popul Ther Clin Pharmacol; 2020 Jun; 27(2):e58-e67. PubMed ID: 32543163
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expensive Drugs for Rare Diseases in Canada: What Value and at What Cost?
    Sirrs S; Anderson H; Jiwani B; Lynd LD; Lun E; Nakagawa B; Regier D; Rizzardo S; McFarlane A
    Healthc Pap; 2023 Jan; 21(1):10-26. PubMed ID: 36692912
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recommendations for the development of rare disease drugs using the accelerated approval pathway and for qualifying biomarkers as primary endpoints.
    Kakkis ED; O'Donovan M; Cox G; Hayes M; Goodsaid F; Tandon PK; Furlong P; Boynton S; Bozic M; Orfali M; Thornton M
    Orphanet J Rare Dis; 2015 Feb; 10():16. PubMed ID: 25757705
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An Orphan Drug Framework (ODF) for Canada.
    Lee DK; Wong B
    J Popul Ther Clin Pharmacol; 2014; 21(1):e42-6. PubMed ID: 24671833
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Why orphan drug coverage reimbursement decision-making needs patient and public involvement.
    Douglas CM; Wilcox E; Burgess M; Lynd LD
    Health Policy; 2015 May; 119(5):588-96. PubMed ID: 25641123
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expensive Drugs for Rare Diseases: "Canada, We Have a Problem Here".
    Lexchin J
    Healthc Pap; 2023 Jan; 21(1):4-8. PubMed ID: 36692911
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Disparity in public funding of systemic therapy for metastatic renal cell carcinoma in Canada.
    Jackson EB; Hotte SJ
    Can Urol Assoc J; 2022 Nov; 16(11):E516-E522. PubMed ID: 35704937
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Addressing the affordability of cancer drugs: using deliberative public engagement to inform health policy.
    Bentley C; Peacock S; Abelson J; Burgess MM; Demers-Payette O; Longstaff H; Tripp L; Lavis JN; Wilson MG
    Health Res Policy Syst; 2019 Feb; 17(1):17. PubMed ID: 30732616
    [TBL] [Abstract][Full Text] [Related]  

  • 38. What can the Canadians and Americans learn from each other's health care systems?
    Weil TP
    Int J Health Plann Manage; 2016 Jul; 31(3):349-70. PubMed ID: 27469581
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The study of drugs for rare disorders: harnessing research contributions by Canadian academic institutions.
    Macleod S; Lasko P; Mackenzie A
    J Popul Ther Clin Pharmacol; 2014; 21(1):e47-55. PubMed ID: 24671865
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Financial conflicts of interest of clinicians making submissions to the pan-Canadian Oncology Drug Review: a descriptive study.
    Lexchin J
    BMJ Open; 2019 Jul; 9(7):e030750. PubMed ID: 31350254
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.